Emicizumab is well tolerated and effective in people with congenital haemophila A regardless of age severity of disease or inhibitor status a scoping review

G YoungS PipeG KenetJ OldenburgE et alJohnny Mahlangu2024-10-172024-10-17WOS2475-0379https://hdl.handle.net/10539/41678Emicizumab is well tolerated and effective in people with congenital haemophila A regardless of age severity of disease or inhibitor status a scoping reviewJournal Article